These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31423623)

  • 1. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
    Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
    Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary eosinophilic disorders: a concise review.
    Pardanani A; Tefferi A
    Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
    Gotlib J
    Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
    Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
    Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
    Yamada Y; Cancelas JA
    Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.